Home –  Medical Studies

Medical Studies

Click on a link to be redirected to a study:

Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects

Plant-based medicines for anxiety disorders, part 2: A review of clinical studies with supporting preclinical evidence

The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system

The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors

Effects of cannabidiol (CBD) on regional cerebral blood flow

Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients

Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug

Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption.

Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: Contribution of 5HT1A receptors and stressful experiences.

Cannabidiol enhances consolidation of explicit fear extinction in humans.

Endocannabinoid system and mood disorders: priming a target for new therapies.

Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test.

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability.

Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report.

Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats.

Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors.

Neuropsychological performance, impulsivity, ADHD symptoms, and novelty seeking in compulsive buying disorder.

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research.

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice.

Cannabidiol in humans-the quest for therapeutic targets.

Safety and side effects of cannabidiol, a Cannabis sativa constituent.

Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.

Endocannabinoid system dysfunction in mood and related disorders.

Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats.

Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.

Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.

Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress.

Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study.

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

Subjective and physiological effects after controlled Sativex and oral THC administration.

The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors.

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.

A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.

Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.

Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids.

Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats.

Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats.

Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition.

Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats.

Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test.

Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats.

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.

Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids.

Pharmacokinetics and pharmacodynamics of cannabinoids.

Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects.

Cannabidiol: an overview of some pharmacological aspects.

Cannabinoids in clinical practice.

Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze.

Effects of ipsapirone and cannabidiol on human experimental anxiety.

Antianxiety effect of cannabidiol in the elevated plus-maze.

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.